Edition:
United Kingdom

Otsuka Holdings Co Ltd (4578.T)

4578.T on Tokyo Stock Exchange

4,880JPY
17 Nov 2017
Change (% chg)

¥-14 (-0.29%)
Prev Close
¥4,894
Open
¥4,896
Day's High
¥4,984
Day's Low
¥4,862
Volume
2,582,300
Avg. Vol
1,295,054
52-wk High
¥5,895
52-wk Low
¥4,290

Chart for

About

Otsuka Holdings Co., Ltd. is a Japan-based pharmaceutical holding company engaged in four business segments. The Medical-related segment is engaged in the sale of ethical drugs, the manufacture, sale and export of curative medicines, as well as the research and development of infusions. The Nutraceuticals-related segment is... (more)

Overall

Beta: 0.44
Market Cap(Mil.): ¥2,513,607.00
Shares Outstanding(Mil.): 557.84
Dividend: 50.00
Yield (%): 2.22

Financials

  Industry Sector
P/E (TTM): -- 31.19 16.41
EPS (TTM): -- -- --
ROI: -- 14.93 10.66
ROE: -- 16.20 14.26

BRIEF-Otsuka Holdings to transfer medical device business to unit

* Says co plans to transfer medical device business to co's wholly owned unit Otsuka Medical Devices Co Ltd, with effective date of Jan. 1, 2018

14 Nov 2017

BRIEF-FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

* FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

09 Nov 2017

BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​

* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​ Source text for Eikon: Further company coverage:

02 Nov 2017

BRIEF-Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type

* Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018

01 Nov 2017

BRIEF-Otsuka and Lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with bipolar I disorder

* unit Otsuka Pharmaceutical Co., Ltd. and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder

12 Oct 2017

BRIEF-Otsuka Holdings, Lundbeck initiate two phase 3 trials of Brexpiprazole

* Otsuka and lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with Bipolar I disorder Source text for Eikon: Further company coverage:

11 Oct 2017

BRIEF-Otsuka Holdings unit raises stake in India-based JV to 80 pct

* Says co's wholly owned unit Otsuka Pharmaceutical Factory, Inc raises stake in JV Otsuka Pharmaceutical India Private Limited to 80 percent

21 Sep 2017

BRIEF-Otsuka Holdings unit acquires Canada-based firm

* Says co's wholly owned unit Otsuka Pharmaceutical Co., Ltd. acquires Canada-based firm, which is mainly engaged in development, manufacture and sales of plant-based foods

01 Sep 2017

BRIEF-Otsuka Holdings unit says ABILIFY MAINTENA® for extended-release injectable suspension approved by U.S. FDA

* Says unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced ABILIFY MAINTENA®(aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and drug administration for the maintenance monotherapy treatment of bipolar I disorder (BP-I) in adults

31 Jul 2017

BRIEF-R&I affirms Otsuka Holdings's rating at "AA-" and changes outlook to stable from negative

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-"-R&I

19 Jul 2017

Earnings vs. Estimates